Celltrion announced that it has begun recruiting patients with inflammatory bowel disease in Ohio for a phase 3 clinical trial of its subcutaneous formulation of biosimilar infliximab, CT-P13 (Inflectra, Remsima). The study is intended to support an application for the formulation to the FDA.
Celltrion has announced that it has begun recruiting patients with inflammatory bowel disease in Ohio for a phase 3 clinical trial of its subcutaneous formulation of biosimilar infliximab, CT-P13 (Inflectra, Remsima). The study is intended to support an application for the formulation to the FDA.
The Republic of Korea—based drug maker indicated that the FDA has exempted the company from having to conduct phase 1 or phase 2 clinical studies, given the amount of clinical data that the company has already generated in support of its submission of the product to the European Medicines Agency (EMA).
The subcutaneous formulation of the biosimilar infliximab has already been submitted for approval in Europe, and the data package supporting its application included data from a study in patients with rheumatoid arthritis (RA).1
The trial investigated the pharmacokinetics, efficacy, and overall safety of the subcutaneous biosimilar versus the already-approved intravenous (IV) version over 1 year. A total of 48 patients were randomly assigned to 4 cohorts: The IV cohort received the IV drug every 8 weeks and the SC cohorts received 90 mg, 120 mg, or 180 mg, respectively, every 2 weeks up to week 54.
Overall, the efficacy and safety results of subcutaneous CT-P13 up to week 54 were comparable with those of the IV formulation, and the safety profiles of the 2 formulations of the drug at week 6 were comparable and consistent with the known profile of infliximab.
The subcutaneous biosimilar was also studied in a phase 1 trial in patients with Crohn disease.2 Forty-four patients were given the IV formulation of CT-P13 at weeks 0 and 2, then randomized to 4 cohorts. One continued to receive the IV biosimilar every 8 weeks, while the second, third, and fourth cohorts each received the subcutaneous biosimilar at doses of 120 mg, 180 mg, and 240 mg, respectively, every 2 weeks up to week 54.
At week 30, overall clinical response rates among cohorts were similar. Clinical remission was numerically higher in the subcutaneous therapy cohorts at week 54. The safety profiles of the IV and subcutaneous formulations were similar.
If the subcutaneous version of the biosimilar is eventually approved, Celltrion has indicated that, in addition to making an appealing choice for patients who are satisfied with treatment with IV infliximab but who prefer or need a subcutaneous route of administration, the new formulation of CT-P13 could compete with brand-name adalimumab (Humira), another subcutaneously administered anti—tumor necrosis factor therapy.
References
1. Yoo DH, Jaworski J, Matyska-Piekarska E, et al. A novel formulation of CT-P13 (infliximab biosimilar) for subcutaneous administration: 1-year results from a part 1 of phase 1/3 randomized controlled trial in patients with active rheumatoid arthritis. Presented at: The European League Against Rheumatism European Congress of Rheumatology 2019; June 12-15, 2019; Madrid, Spain. Abstract FRI0128.
2. Byong DY, Byung IJ, Borzan V, et al. A novel formulation of CT-P13 (infliximab biosimilar) for subcutaneous administration: 1-year result from a phase 1 open-label randomized controlled trial in patients with active Crohn’s disease. Presented at: Digestive Disease Week 2019; May 18-21, 2019; San Diego, CA. Abstract Tu1715.
The Trump Administration’s Drug Price Actions and Why US Prices Are Already Sky-High
May 17th 2025While the Trump administration’s latest executive order touts sweeping drug price cuts through international benchmarking, the broader pharmaceutical pricing crisis in the US reveals a far more complex web of development costs, profit incentives, and absent price controls—raising the question of whether any single policy, including potential drug tariffs, can truly untangle it.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
Switching From Avastin to Bevacizumab-bvzr in CRC, NSCLC Can Reduce Medicare Costs
May 10th 2025Monthly savings from fully converting Medicare patients with metastatic colorectal cancer (CRC) and non-squamous metastatic non-small cell lung cancer (NSCLC) from reference bevacizumab to bevacizumab-bvzr could fund 13,887 and 8,959 additional patient-months of treatment, respectively, according to a cost-effectiveness study.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Samsung Bioepis Report Signals Turning Point for US Biosimilars
May 1st 2025A wave of biosimilar approvals, aggressive pricing strategies, and a regulatory sea change are setting the stage for unprecedented momentum in the US biologics market, with 2025 already proving to be a landmark year in reshaping cost, access, and innovation across therapeutic areas.